PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of anclinmicBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleAnnals of Clinical Microbiology and Antimicrobials
 
Ann Clin Microbiol Antimicrob. 2017; 16: 9.
Published online 2017 March 6. doi:  10.1186/s12941-017-0184-2
PMCID: PMC5338084

Cryptococcal meningoencephalitis in HIV/AIDS: when to start antiretroviral therapy?

The institution of antiretroviral therapy (ART) in HIV-infected individuals with the goal of achieving virologic control and restoring immunity has led to substantial declines in AIDS-related complications, non-AIDS related morbidity, and improved survival [1]. In addition to the benefit provided at the individual level, it is also a crucial intervention to reduce HIV-transmission. Current treatment guidelines continue to emphasize early initiation of ART among individuals presenting at any stage of HIV-infection regardless of their CD4 cell count [1].

There is also an overall consensus that ART should be initiated within the first 2 weeks in individuals with advanced HIV-infection presenting with an AIDS-defining opportunistic infection with the possible exception of cryptococcal meningoencephalitis. However, the most recent update of the treatment guidelines of the International Antiviral Society-USA recommend considering ART within 2 weeks of diagnosis of cryptococcal meningoencephalitis in resource-rich settings where there is increased availability of optimal antifungal therapy (amphotericin B formulations and flucytosine); and means to monitor and aggressively treat increased intracranial pressure [1].

Worldwide, the highest burden of CNS cryptococcosis occurs in Sub-Saharan Africa and Southeast Asia, however, a substantial burden of disease occurs in high-income settings [24]. In the US, the Southeast has the highest rates of AIDS-associated hospitalization and mortality due to cryptococcosis [5]. Restoring immune function by the institution of ART is a crucial intervention in HIV-associated cryptococcal meningoencephalitis [2, 3]. We suggest that the timing of ART initiation should be individualized in every case considering host and fungal-related ones.

The intracranial life of Cryptococcus

In patients with HIV/AIDS, there are two distinct clinical scenarios of central nervous system (CNS) cryptococcosis: (a) cryptococcal meningoencephalitis or parenchymal presentations in the setting of advanced immunosuppression; and (b) cryptococcal immune reconstitution inflammatory syndrome (IRIS) after the initiation of ART (Table 1).

Table 1
Differences in the pathogenesis and clinical manifestations of untreated CNS cryptococcosis and cryptococcal associated IRIS in patients with HIV/AIDS

Cryptococcal meningoencephalitis in advanced HIV-infection

Cryptococci encounters limited immunological resistance during its route of entry into a human host with advanced HIV-associated immunosuppression. Cryptococcus establishes pulmonary infection through inhalation of its spores or desiccated yeast cells [57]. Once it reaches the lung parenchyma, Cryptococci enters the bloodstream and travels to the CNS [59]. The CNS vasculature system plays a crucial role in the mechanism of invasion of this fungal pathogen [9]. After large arteries from the carotid and vertebral circulations merge at the Circle of Willis, medium-size cerebral arteries branch into smaller pial arteries and arterioles that run along the surface of the brain. Pial arteries are constituted by an endothelial cell layer, a smooth muscle cell layer and an outer adventitial layer of leptomeningeal cells [10]. The adventitia is separated from brain tissue by the Virchow-Robin space as these arterioles penetrate deeper into the brain parenchyma (Fig. 1A). The Virchow-Robin space surround the walls of arteries, arterioles, veins, and venules as they course from the subarachnoid space and while penetrating through the brain parenchyma and plays an important role in the drainage of interstitial fluid from the brain parenchyma [10].

Fig. 1
A Pattern of invasion of Cryptococcus neoformans into intracranial compartments in the setting of advanced HIV-infection*. a Arachnoid; b subarachnoid space; c pia mater; d brain parenchima; 1 Cryptococci exiting arteries into the subarachnoid ...

Cryptococci enters the cerebrospinal fluid (CSF), perivascular spaces, and brain parenchyma via transcellular crossing of the endothelial cells of blood brain barrier (BBB) but not of the blood-CSF barrier at the choroid plexus, and importantly, without affecting the integrity of the BBB [9, 11]. Other potential mechanism for entry into the CNS includes a “Trojan horse” whereby Cryptococcus enters hidden inside mononuclear cells [6]. Apparently, Cryptococci has avidity for the neurotransmitter-rich cerebral microenvironment surrounding the pial arterioles penetrating the brain parenchyma and for reaching the safe haven of the perivascular spaces [6, 12] (Fig. 1A). Indeed, leptomeningeal cells around arteries and arterioles in the human brain and in the subarachnoid space contain a high concentration of catechol-O-methyltransferase and pial arteries are densely innervated by perivascular nerves [10] providing a suitable environment where this yeast can procure substrates to synthetize melanin and overcome oxidative stress and phagocytosis [6].

In patients with HIV/AIDS, surgical neuropathological examinations and autopsy case series have consistently reported large numbers of yeasts in the subarachnoid space (Fig. 1B) and in the perivascular spaces (gelatinous pseudocysts or flask abscesses), particularly along the lenticulostriate arteries entering the basal ganglia through the anterior perforated substance [1317]. Additionally, these reports have consistently demonstrated a paucity of inflammation in the meninges and subarachnoid space with only limited numbers of lymphocytes and few plasmocytes, and therefore the concept of “cryptococcal meningitis” may in fact constitute a misnomer [13, 14]. Since pia mater separates the subarachnoid space from underlying brain; and CSF from the interstitial fluid [18], Cryptococci likely enters different spaces at different segments of the microvasculature [10]: (a) during the trajectories of pial arterioles inside the subarachnoid space allowing access of the yeast into the CSF; (b) through penetrating arterioles after the subpial space allowing Cryptococci entering the perivascular spaces (Fig. 1C); and (c) via parenchymal capillaries that facilitates for this fungus, albeit in lesser degree, entering into the brain parenchyma (Fig. 1A) [10]. In support of the above pathways of invasion and pathological descriptions of CNS cryptococcosis, neuroimaging case series described dilated perivascular as punctate or oval hyper intense areas on T2-weighted images in the basal ganglia and brainstem. In some cases, high fungal burden promotes confluence of gelatinous pseudocysts and extend into the brain parenchyma leading to appearance of cryptococcomas [1923]. The fungal burden identified in many patients may reach a degree of more than 1 million yeasts per milliliter of CSF, with greater CSF polysaccharide antigen titers, and higher degrees of intracranial pressures Abnormal dural or leptomeningeal enhancement is rarely described in these case series [8].

The spectrum of disease caused by CNS cryptococcosis in advanced HIV-infection is mostly due to intracranial hypertension caused by CSF outflow obstruction (i.e. subacute onset of headache, nausea, vomiting, fever, decreased hearing, decreased vision, seizures, or altered mentation) and less frequently symptoms of meningeal inflammation [12]. The precise mechanism for ICH is not fully elucidated, however, a reduced rate of removal of CSF precipitated by CSF outflow blockage caused by deposition of capsular polysaccharide and yeasts at arachnoid villi [12, 2431]. In addition, drainage of interstitial fluid into the perivascular spaces is disrupted by the large number of yeast present in both the perivascular spaces and in the brain parenchyma [18, 32, 33] (Fig. 1A). Some individuals may manifest with parenchymal brain involvement with focal neurological signs caused by expanding cryptococcomas [1923]. In summary, the spectrum of clinical, pathological, and imaging of CNS cryptococcosis in the setting of HIV/AIDS reflects the pathological mechanism of invasion of this fungal pathogen leading to a high fungal burden, a paucity of inflammation in the subarachnoid space and meninges, and substantial alterations in the dynamics of CSF and interstitial fluid homeostasis resulting in increased intracranial pressure [12].

Cryptococcal immune reconstitution inflammatory syndrome

Despite its sophisticated role, the brain is vulnerable to events that produce rapid increases in intracranial pressure with potential devastating consequences [34]. This susceptibility resides in the fact that the brain is contained in a rigid and rudimentary cranium that restricts any increase in volume including brain edema or any alteration of the fine balance of the production, circulation or reabsorption of CSF [34, 35]. The expansion of one of the intracranial component (i.e., cerebrum, cerebrospinal fluid or intravascular blood) is at the expense of a reduction in another component. In this context, immune recovery associated to the initiation of ART in patients with cryptococcal meningoencephalitis may sometimes precipitates an exuberant cellular and molecular inflammatory battle against Cryptococci including components of its capsular polysaccharide [7, 8]. This response occurs predominantly in the subarachnoid space, leptomeninges, or in the Virchow-Robin spaces, which may disrupt the intracranial volume balance with potential life-threatening consequences.

With the increasing deployment and scale-up of ART in many settings, there is an overarching urgency to initiate ART in those identified with HIV-infection including those with advanced immunosuppression [1]. Patients with AIDS presenting with cryptococcal meningoencephalitis and CD4 cell counts <100 cell/µL, ART should be initiated as soon as possible. However, there are competing risks and benefits that must be balanced. In one hand, starting ART within the first 2 weeks of antifungal therapy may paradoxically induce restoration of pathogen specific immunity leading to cryptococcal IRIS which can be detrimental in a patient population that is immunologically unstable and clinically fragile [7, 8]. On the other hand, starting ART later may increase the chances of delaying fungal clearance and of the development of other life-threatening opportunistic infections. Cryptococcal associated IRIS occurs in approximately 13–30% of HIV-infected individuals and most cases occur in the first few months after initiating ART [2, 36]. Pathogen and host factors are important players in leading to IRIS: a high fungal burden and a poor proinflammatory response present prior to instituting ART (Cryptococcus neoformans promotes Th2 immune responses) [7, 8, 36]. In African cohorts, approximately one third of cases of CNS cryptococcosis present in patients already receiving ART. The institution of ART in this patient population may clinically unmask in the form of an IRIS, the previously undetected residence of Cryptococci in the CNS [7, 8]. Therefore, prior to starting ART, screening for asymptomatic cryptococcal antigenemia with lateral flow assays is considered best practice [8].

Cryptococcal associated IRIS is characterized by accumulation of cryptococcal polysaccharide in the subarachnoid space producing rapid chemokine-mediated monocyte recruitment into the subarachnoid space and CD4 cell redistribution into the CNS [2, 36]. This immunological response is dysregulated and causes inadequate cryptococcal killing and clearance of the fungus within the neuraxis. Patients with HIV/AIDS and with high fungal burden at the time of diagnosis seem to be at the highest risk of IRIS, particularly with rapid restoration of immune activity following ART [37, 39, 40]. However, most of the reports of IRIS associated with CNS cryptococcosis appear to be meningeal involvement in terms of its clinical presentation and also by evidence of leptomeningitis in T1-weighted contrast images [22]. CSF examination reveals important degrees of pleocytosis and high opening pressures but negative cultures [2, 36]. Cryptococcal associated IRIS may manifest with a constellation of symptoms associated with leptomeningitis and intracranial hypertension [38, 39]. This abrupt process occurring a few weeks or months after the institution of ART may manifest clinically with clinical neurologic deterioration; and sometimes with seizures, visual and hearing loss, or mass effect with herniation. CNS cryptococcosis associated IRIS should be considered in patients with HIV infection meeting all or some of the following criteria [38]: (a) CSF culture-confirmed first episode of cryptococcal meningoencephalitis, (b) resolution of cryptococcal meningoencephalitis symptoms before starting ART, (3) self-reported adherence to antifungal therapy and ART, (4) recurrence of symptoms (headache, nausea, vomiting, visual disturbance or others) after initiation of ART, (5) evidence of immunological and/or virologic response to ART, and (6) no alternative diagnosis found on laboratory testing and repeated clinical assessment. These clinical diagnostic criteria are imprecise but provide a framework for clinicians to consider this diagnostic possibility. Recent evidence suggests that starting ARTs within 1–2 weeks of diagnosis of CNS cryptococcosis is associated with excess mortality compared to starting ARTs at 5 weeks [8, 40]. The excess of deaths in the early ART group appeared to be caused by cryptococcal meningoencephalitis and not from Cryptococcal IRIS [8, 40]. Although the incidence of Cryptococcal associated IRIS was not different in the two groups, the findings of this study does suggest that ART instituted within 1–2 weeks does not have a meaningful impact in reducing CNS cryptococcosis associated mortality.

We suggest that the timing of initiation of ART should be individualized considering host factors such as the degree of inflammatory response (level of CSF pleocytosis and C-reactive protein level) and the fungal burden (cryptococcal antigen in CSF at the time of diagnosis and initial opening pressure); or assessing the sterilization of CSF at the end of the second week of optimal antifungal therapy. We believe that starting ART at 5 weeks or later should be considered particularly for those patients with: (a) extremely low CD4 cell counts; (b) cryptococcosis unveiling previously undiagnosed HIV infection; (c) CSF culture positive at 2 weeks despite standard antifungal treatment; and d) among those with high fungal burden as suggested by initial high opening pressure combined with cryptococcal antigen titer in CSF > 1:1056 [37].

Globally, AIDS-associated cryptococcal meningoencephalitis is a deadly disease causing approximately 20–25% of HIV-related mortality [2]. The initiation of fungicidal therapy with amphotericin B and flucytosine “stirs the pot” in the affected CNS areas (Fig. 1A) by promoting cell death and releasing large amounts of capsular polysaccharide. During the induction phase of antifungal therapy, efforts should focus on ensuring optimal medical management and ensuring sterilization of CSF while aggressively managing intracranial hypertension with CSF drainage. In this context, deferring ART for 5 weeks or longer, may offer a margin of safety to reduce the chances of IRIS occurring in the confined space of the cranium.

Finally, the persistent occurrence of cryptococcal infection in individuals with HIV-infection living in high-income settings unveils two major concerns: (a) the large number, in some settings, of undiagnosed cases of HIV infection who are unaware of their infection; and (b) the complex interplay of individual, social, and healthcare barriers facing individuals living with HIV-infection to enter into the HIV continuum of care.

Authors’ contributions

CFP wrote the first draft. All authors contributed with subsequent versions. All authors read and approved the final manuscript.

Acknowledgements

None.

Competing interests

The authors declare that they have no competing interests.

Contributor Information

Carlos Franco-Paredes, moc.liamg@sederap.ocnarf.solrac.

Daniel B. Chastain, gro.hmpp@niatsahcd.

Alfonso J. Rodriguez-Morales, oc.ude.ptu@mzeugirdora.

Luis A. Marcos, moc.oohay@zrlsocram.

References

1. Gunthard HF, Saag MC, Benson CA, Del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. 2016 recommendations of the International Antiviral-USA Panel. JAMA. 2016;316(2):191–210. doi: 10.1001/jama.2016.8900. [PMC free article] [PubMed] [Cross Ref]
2. Meya DB, Manabe YC, Boulware DR, Janoff EN. The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. Curr Opin Infect Dis. 2016;29:10–22. doi: 10.1097/QCO.0000000000000224. [PMC free article] [PubMed] [Cross Ref]
3. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016;30:179–206. doi: 10.1016/j.idc.2015.10.006. [PubMed] [Cross Ref]
4. Perfect JR. Efficient killing of a sugar-coated yeast. N Engl J Med. 2013;368:1354–1355. doi: 10.1056/NEJMe1302038. [PubMed] [Cross Ref]
5. Pyrgos V, Seitz AE, Steiner CA, Rebecca Prevots D, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLoS ONE. 2013;8(2):e56269. doi: 10.1371/journal.pone.0056269. [PMC free article] [PubMed] [Cross Ref]
6. Coelho C, Bocca AL, Casadevall A. The intracellular life of Cryptococcus neoformans. Ann Rev Pathol Mech Dis. 2014;9:219–238. doi: 10.1146/annurev-pathol-012513-104653. [PMC free article] [PubMed] [Cross Ref]
7. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322. doi: 10.1086/649858. [PubMed] [Cross Ref]
8. Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015;78:49–54. doi: 10.1016/j.fgb.2014.10.003. [PMC free article] [PubMed] [Cross Ref]
9. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, Dam T, et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun. 2004;72(9):4985. doi: 10.1128/IAI.72.9.4985-4995.2004. [PMC free article] [PubMed] [Cross Ref]
10. Zhang ET, Inman CBE, Weller RO. Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J Anat. 1990;170:111–123. [PubMed]
11. Dando SJ, Mackay-Sim A, Norton R, Currie BJ, John J, Ekberg JAK, Batzloff M, Ulett GC, Beacham IR. Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microb Rev. 2014;27(4):691–726. doi: 10.1128/CMR.00118-13. [PMC free article] [PubMed] [Cross Ref]
12. Franco-Paredes C, Sellers B, Hayes A, Chane T, Patel K, Marr K. Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis. 2014;15(3):348–355. doi: 10.1016/S1473-3099(14)70945-4. [PMC free article] [PubMed] [Cross Ref]
13. Miller DC, Najjar S, Budzilovich N. Neuropathology of AIDS in surgical biopsies. Neurosurg Clin North Am. 1994;5:57–70. [PubMed]
14. Miller DC. Dexamethasone in cryptococcal meningitis. N Engl J Med. 2016;375(2):189. [PubMed]
15. Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol. 1996;27(8):839–847. doi: 10.1016/S0046-8177(96)90459-1. [PubMed] [Cross Ref]
16. Klock C, Cerski M, Goldani LZ. Histopathological aspects of neurocyptococcosis in HIV-Infected patients: autopsy report of 45 patients. Int J Surg Pathol. 2009;17(6):444–448. doi: 10.1177/1066896908320550. [PubMed] [Cross Ref]
17. Shibuya K, Coulson WF, Wollman JS, Wakayama M, Ando T, Oharaseki T, Takahashi K, Naoe S. Histopathology of cryptococcosis and other fungal infections in patients with acquired immunodeficiency syndrome. Int J infect Dis. 2001;5(2):78–85. doi: 10.1016/S1201-9712(01)90030-X. [PubMed] [Cross Ref]
18. Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009;117:1–14. doi: 10.1007/s00401-008-0457-0. [PubMed] [Cross Ref]
19. Kwee RM, Kwee TC. Virchow-Robin spaces at MR imaging. Radiographics. 2007;27:1071–1086. doi: 10.1148/rg.274065722. [PubMed] [Cross Ref]
20. Matthews VP, Alo PL, Glass JD, McArthur JC. AIDS-related CNS cryptococcosis: radiologic-pathologic correlation. AJNR. 1992;13:1477–1486. [PubMed]
21. Miskiel KA, Hall-Craggs MA, Miller RF, Kendall BE, Wilkinson ID, Paley MN, Harrison MJG. The spectrum of MRI findings in CNS cryptococcosis in AIDS. Clin Radiol. 1996;51:842–850. doi: 10.1016/S0009-9260(96)80080-8. [PubMed] [Cross Ref]
22. Katchanov J, Branding G, Jefferys L, Arasteh K, Stocker H, Siebert E. Neuroimaging of HIV-associated cryptococcal meningitis: comparison of magnetic resonance imaging findings in patients with and without immune reconstitution. Int J STD AIDS. 2016;27(2):110–117. doi: 10.1177/0956462415574633. [PubMed] [Cross Ref]
23. Berkefeld J, Enzensberger W, Lanfermann H. Cryptococcus meningoencephalitis in AIDS: parenchymal and meningeal forms. Neuroradiology. 1999;41:129–133. doi: 10.1007/s002340050717. [PubMed] [Cross Ref]
24. Lee SC, Casadevall A, Dickson DW. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningitis. Am J Pathol. 1996;148(4):1267–1274. [PubMed]
25. Lee SC, Casadevall A. Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Clin Infect Dis. 1996;23:194–195. doi: 10.1093/clinids/23.1.194. [PubMed] [Cross Ref]
26. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal buden and ocutome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23:701–706. [PubMed]
27. Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med. 1991;91:267–272. doi: 10.1016/0002-9343(91)90126-I. [PubMed] [Cross Ref]
28. Hirano A, Zimmerman HM, Levine S. The fine structure of cerebral fluid accumulation. IV. On the nature and origin of extracellular fluids following cryptococcal polysaccharide implantation. Am J Pathol. 1964;45:1–19. [PubMed]
29. Macsween KF, Bicanic T, Brouwer AE, Marsh H, Macallan DC, Harrison TS. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect. 2005;51:e221–e224. doi: 10.1016/j.jinf.2005.02.010. [PubMed] [Cross Ref]
30. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30:47–54. doi: 10.1086/313603. [PubMed] [Cross Ref]
31. Bach MC, Tally PW, Godofsky EW. Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension. Neurosurgery. 1997;41:1280. doi: 10.1097/00006123-199712000-00008. [PubMed] [Cross Ref]
32. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimers disease. Nat Rev Neurosci. 2004;5:347–360. doi: 10.1038/nrn1387. [PubMed] [Cross Ref]
33. Sakka L, Coll G, Chazal J. Anatomy and physiology of cerebrospinal fluid. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128:309–316. doi: 10.1016/j.anorl.2011.03.002. [PubMed] [Cross Ref]
34. Fishman RA. Brain edema. N Engl J Med. 1975;293(14):706–711. doi: 10.1056/NEJM197510022931407. [PubMed] [Cross Ref]
35. Ropper AH. Brain in a box. N Engl J Med. 2012;367(26):2539–2541. doi: 10.1056/NEJMe1212289. [PubMed] [Cross Ref]
36. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, Lee SJ, Kaugu A, Janoff EN, Bohjanen PR. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010;7(12):e1000384. doi: 10.1371/journal.pmed.1000384. [PMC free article] [PubMed] [Cross Ref]
37. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736–745. doi: 10.1093/cid/cit794. [PMC free article] [PubMed] [Cross Ref]
38. Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, Hayes M, Jaffar S, Harrison T. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immun Defic Syndr. 2009;51(2):130–134. doi: 10.1097/QAI.0b013e3181a56f2e. [PubMed] [Cross Ref]
39. Yan S, Chen L, Wu W, Li Z, Fu Z, Zhang H, Xue J, Hu Y, Mou J, Fu C. Paradoxical immune reconstitution inflammatory syndrome associated with cryptococcal meningitis in China: a 5-year retrospective cohort study. Clin Microb Infect. 2015;21:379. doi: 10.1016/j.cmi.2014.08.023. [PubMed] [Cross Ref]
40. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;26:2487–2498. doi: 10.1056/NEJMoa1312884. [PMC free article] [PubMed] [Cross Ref]

Articles from Annals of Clinical Microbiology and Antimicrobials are provided here courtesy of BioMed Central